Idera Pharmaceuticals (NASDAQ:IDRA) bucked the biotech sell-off last month by gaining more than 20%. The company, which currently doesn't have any products on the market, is working on an intriguing new cancer therapy for patients with specific genetic mutations and in the fourth quarter, Idera Pharmaceuticals plans to release data showing whether or not IMO 8400 is effective at treating a rare form of cancer known as Waldenstrom's macroglobulinemia.

View the slideshow to learn more about Idera Pharmaceuticals and what's driving interest in its shares higher.